Asia’s infectious disease serology test kits market is entering a new growth phase, supported by expanding universal health coverage, blood screening mandates, and stronger infectious disease surveillance across the region. According to IndexBox, long-term volume growth across Asia is projected in the 6% to 9% CAGR range from 2026 to 2035.
This growth is being driven by sustained demand for hepatitis B, hepatitis C, and HIV testing, alongside rising use of syphilis, dengue, and TORCH panel assays. At the same time, healthcare systems are moving toward higher-throughput and more automated diagnostic workflows, especially across hospital chains, reference laboratories, and national screening programmes.
Key Growth Drivers and High-Demand Segments
Several factors are shaping Asia’s serology test kit outlook in 2026. Large hospital networks and reference laboratories are increasingly adopting chemiluminescence immunoassay platforms, while rapid diagnostic test demand continues to grow through decentralised primary care, antenatal testing, and rural outreach programmes.
At the same time, demand is rising across several key areas:
- Hepatitis B, hepatitis C, and HIV serology testing
- Syphilis, dengue, and TORCH panel assays
- Rapid diagnostic tests for decentralised and outreach screening
- CLIA platforms for higher-throughput laboratory testing
- Multiplex serology panels for faster infectious disease investigation
What This Means for Manufacturers
Southeast Asia remains one of the most attractive regions for MedTech and IVD expansion. The companies that succeed are those that plan beyond the first approval.
A stronger market access strategy should consider:
- Regulatory requirements across each target country
- The right sequence for registration and commercial rollout
- Distributor capability, not just market coverage
- Importation and local representation requirements
- Pricing and tender participation
- Supply continuity and post-market compliance
This integrated approach helps manufacturers reduce risk, avoid delays, and build a more practical path to growth.
Planning to enter Southeast Asia’s medical device or IVD market? Contact Andaman Medical to discuss the regulatory requirements and market access steps needed to prepare for your product launch.